Mayne Pharma
Mr Frank Condella was appointed to the Board on 30 May 2018 and was appointed Chair in September 2021.
Mr Condella, a US resident, has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes CEO of Juniper Pharmaceuticals, a CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as CEO of Skyepharma Plc, President of European operations at IVAX (Teva), CEO of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella’s previous board experience includes Chair of Skyepharma Plc until it merged with Vectura, Vice Chair of Vectura Plc, Independent Director for Fertin Pharma A/S (Denmark), Independent Director for Palladio Biosciences Inc (US), Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, and Chair of the PKD Foundation. Mr Condella holds a Bachelor of Science in Pharmacy and an M.B.A. from Northeastern University, Boston.
Mr Condella is also Chair of the Remuneration and People Committee and the Nomination Committee and a member of the Science and Technology Committee.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Mayne Pharma
1 followers
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.